Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
Phase 3
Completed
- Conditions
- Infections, Nosocomial
- Registration Number
- NCT00150332
- Lead Sponsor
- Pfizer
- Brief Summary
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- infection due to methicillin-resistant Staphylococcus aureus
Exclusion Criteria
- hypersensitivity to linezolid
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Resolution of infection at the time of completion of therapy
- Secondary Outcome Measures
Name Time Method Adverse events
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie linezolid's efficacy against MRSA in Japanese patients as studied in NCT00150332?
How does linezolid compare to standard-of-care antibiotics like vancomycin in treating MRSA infections in Japan?
Are there specific biomarkers that predict patient response to linezolid in MRSA infections as observed in NCT00150332?
What adverse events were reported in NCT00150332 and how do they align with linezolid's known safety profile?
What is the role of linezolid in the broader context of oxazolidinone antibiotics for MRSA treatment in Japan?
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇯🇵Okayama, Japan
Pfizer Investigational Site🇯🇵Okayama, Japan